750 related articles for article (PubMed ID: 24237632)
41. Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid.
McNamara NA; Dang LT; Sturza J; Ziobro JM; Fedak Romanowski EM; Smith GC; Joshi SM; Leber SM; Carlson M; Robertson P; Shellhaas RA
Epilepsia; 2020 Aug; 61(8):e85-e89. PubMed ID: 32614070
[TBL] [Abstract][Full Text] [Related]
42. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
43. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
[TBL] [Abstract][Full Text] [Related]
44. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
45. Cannabidiol for Epilepsy: New Hope on the Horizon?
Sanmartin PE; Detyniecki K
Clin Ther; 2018 Sep; 40(9):1438-1441. PubMed ID: 30150078
[TBL] [Abstract][Full Text] [Related]
46. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
47. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study.
Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H
Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352
[TBL] [Abstract][Full Text] [Related]
48. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
[TBL] [Abstract][Full Text] [Related]
49. Cannabidiol in the Treatment of Epilepsy.
von Wrede R; Helmstaedter C; Surges R
Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
[TBL] [Abstract][Full Text] [Related]
50. Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.
Navarro CE
Neurol Sci; 2023 Jan; 44(1):297-304. PubMed ID: 36129615
[TBL] [Abstract][Full Text] [Related]
51. Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study.
Marshall J; Skrobanski H; Moore-Ramdin L; Kornalska K; Swinburn P; Bowditch S
J Child Neurol; 2023 May; 38(6-7):394-406. PubMed ID: 37455396
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
53. The case for medical marijuana in epilepsy.
Maa E; Figi P
Epilepsia; 2014 Jun; 55(6):783-6. PubMed ID: 24854149
[TBL] [Abstract][Full Text] [Related]
54. Medical Marijuana in the Pediatric Population With Epilepsy-What You Should Know.
Markle M; Nativio DG
J Pediatr Health Care; 2019; 33(6):626-632. PubMed ID: 31160106
[TBL] [Abstract][Full Text] [Related]
55. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D
Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
[TBL] [Abstract][Full Text] [Related]
56. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
57. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
58. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
59. Cannabis for paediatric epilepsy: challenges and conundrums.
Chen KA; Farrar MA; Cardamone M; Lawson JA
Med J Aust; 2018 Feb; 208(3):132-136. PubMed ID: 29438649
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of cannabis for treating children with refractory epilepsy.
Neale M
Nurs Child Young People; 2017 Sep; 29(7):32-37. PubMed ID: 29115760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
